Carbapenem Resistance and ESBL-Producing Enterobacteriaceae in Patients with Urological Infections from 2012 to 2021 in Three Korean Hospitals
Diagnostics · 11.08.2025 · 15 (16) · 2004
DOI: 10.3390/diagnostics15162004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 11.08.2025. Verfasst von Seon Beom Jo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Korea University Guro Hospital, Seoul 08308, Republic of Korea. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea University.
Abstract (Originalsprache)
Background
Urinary tract infections (UTIs) remain a leading cause of community- and hospital-onset bacterial infections worldwide. Although many countries have implemented antimicrobial resistance (AMR) surveillance systems, longitudinal multicenter data on key uropathogens in Korea remain limited.
Methods
We retrospectively evaluated Escherichia coli and Klebsiella pneumoniae isolates from patients with clinically diagnosed UTIs at three tertiary-care Korean hospitals (2012–2021). Using a harmonized Observational Medical Outcomes Partnership Common Data Model (OMOP CDM), we analyzed antibiotic susceptibility based on Clinical and Laboratory Standards Institute breakpoints. Trends in resistance to key antibiotics (including fluoroquinolones, cephalosporins, and carbapenems) were assessed using the Cochran–Armitage test.
Results
From 2012 to 2021, ESBL-producing E. coli and K. pneumoniae increased from 24.1% to 38.2% and 39.2% to 46.4%, respectively. The rates for K. pneumoniae remained stable over the last 6 years, and for E. coli, they remained stable over the last 3 years. Resistance rates for E. coli increased from 44.5% to 60.0% (ciprofloxacin) and from 26.3% to 40.2% (cefotaxime), while carbapenem resistance (ertapenem) remained low, at 0.3% to 1.2%. In contrast, K. pneumoniae exhibited high resistance levels to fluoroquinolones, cephalosporins, and other broad-spectrum antibiotics, with notable increases in resistance to ertapenem, from 3.0% to 18.1%, and imipenem, from 0.4% to 16.8%. This escalation mainly stemmed from the rise in ertapenem (6.6% to 17.0%) and imipenem (0.8% to 14.6%) resistance rates among Klebsiella-ESBL producers.
Conclusions
We conclude that in Korea, the proportion of ESBL-producing E. coli and K. pneumoniae increased significantly from 2012 to 2018 and has since remained stable for the last 3 years (E. coli) and 6 years (K. pneumoniae). Although carbapenem resistance in E. coli remains low, K. pneumoniae has experienced a significant rise, primarily attributable to its ESBL-producing strains. These findings underscore the importance of vigilant antimicrobial stewardship and continuous surveillance to guide empirical UTI therapies in Korean clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Korea University Guro Hospital, Seoul 08308, Republic of Korea.
- Department of Cardiology, Korea University Anam Hospital, Seoul 02841, Republic of Korea.
ORCID-Profile: Seon Beom Jo, Sun Tae Ahn, Hyung Joon Joo, Jong Wook Kim
Förderung
- Korea University
Zitieren
APA
Jo, S. B., Ahn, S. T., Joo, H. J., Kim, J. W., & Oh, M. M. (2025). Carbapenem Resistance and ESBL-Producing Enterobacteriaceae in Patients with Urological Infections from 2012 to 2021 in Three Korean Hospitals. Diagnostics, 15(16), 2004. https://doi.org/10.3390/diagnostics15162004
Vancouver
Jo SB, Ahn ST, Joo HJ, Kim JW, Oh MM. Carbapenem Resistance and ESBL-Producing Enterobacteriaceae in Patients with Urological Infections from 2012 to 2021 in Three Korean Hospitals. Diagnostics. 2025;15(16):2004. doi:10.3390/diagnostics15162004
BibTeX
@article{Jo2025,
author = {Jo, Seon Beom and Ahn, Sun Tae and Joo, Hyung Joon and Kim, Jong Wook and Oh, Mi Mi},
title = {Carbapenem Resistance and ESBL-Producing Enterobacteriaceae in Patients with Urological Infections from 2012 to 2021 in Three Korean Hospitals},
journal = {Diagnostics},
year = {2025},
volume = {15},
number = {16},
pages = {2004},
doi = {10.3390/diagnostics15162004}
}
EUVIMED